Search

Your search keyword '"Singh, Prianka"' showing total 44 results
Start Over Author "Singh, Prianka"
44 results on '"Singh, Prianka"'

2. Caregiver burden by treatment and clinical characteristics of patients with glioblastoma

Author

Au, Trang H, Willis, Connor, Reblin, Maija, Peters, Katherine B, Nghiemphu, Phioanh Leia, Taylor, Jennie W, Colman, Howard, Cohen, Adam L, Ormond, D Ryan, Chakravarti, Arnab, Willmarth, Nicole, Menon, Jyothi, Ma, Junjie, Bauer, Hillevi, Watanabe, Alexandre H, Ulrich, Cornelia M, Singh, Prianka, Marshall, Alexander, Korytowsky, Beata, Stenehjem, David, and Brixner, Diana

Subjects
Health Services and Systems, Nursing, Health Sciences, Brain Disorders, Rare Diseases, Behavioral and Social Science, Brain Cancer, Cancer, Clinical Research, Aging, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adolescent, Adult, Caregiver Burden, Caregivers, Cost of Illness, Glioblastoma, Humans, Quality of Life, Surveys and Questionnaires, GBM, Caregiver, Cognitive dysfunction, Medical and Health Sciences, Psychology and Cognitive Sciences, Oncology & Carcinogenesis, Biomedical and clinical sciences, Health sciences, Psychology
Abstract

BackgroundGlioblastoma is an incurable disease with a poor prognosis. For caregivers of people with glioblastoma, the burden of care can be high. Patients often present with different clinical characteristics, which may impact caregiver burden in different ways. This study aimed to evaluate associations between patient clinical characteristics and caregiver burden/quality of life (QoL).MethodsCaregiver-patient dyads were enrolled at 7 academic cancer centers in the United States. Eligible caregiver participants were self-reported as the primary caregiver of an adult living with glioblastoma and completed a caregiver burden survey. Eligible patients were age ≥ 18 years at glioblastoma diagnosis and alive when their respective caregiver entered the study, with the presence of cognitive dysfunction confirmed by the caregiver. Data were analyzed with descriptive statistics and multivariable analyses.ResultsThe final cohort included 167 dyads. Poor patient performance status resulted in patient difficulty with mental tasks, more caregiving tasks, and increased caregiving time. Language problems were reported in patients with left-sided lesions. Patient confusion was negatively associated with all caregiver domains: emotional health, social health, general health, ability to work, confidence in finances, and overall QoL. Better caregiver QoL was observed in patients with frontal lobe lesions versus non-frontal lobe lesions.ConclusionThis study reinforced that patient performance status is a critical clinical factor that significantly affects caregiver burden, caregiving tasks, and caregiver time. Additionally, patient confusion affects multiple facets of caregiver burden/QoL. These results could be used to support guided intervention for caregiver support, customized to the patient experience.

Published
2022

6. Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma

Author

Au, Trang H., Willis, Connor, Reblin, Maija, Peters, Katherine B., Nghiemphu, Phioanh Leia, Taylor, Jennie W., Colman, Howard, Cohen, Adam L., Ormond, D. Ryan, Chakravarti, Arnab, Willmarth, Nicole, Menon, Jyothi, Ma, Junjie, Bauer, Hillevi, Watanabe, Alexandre H., Ulrich, Cornelia M., Singh, Prianka, Marshall, Alexander, Korytowsky, Beata, Stenehjem, David, and Brixner, Diana

Published
2022
Full Text
View/download PDF

8. Disease-free survival (DFS) as a surrogate endpoint (SE) for overall survival (OS) in early-stage resected esophageal/gastroesophageal junction cancer (EC/GEJC): An analysis of SEER-Medicare data.

Author

Ajani, Jaffer A., primary, Leung, Lisa, additional, Kanters, Steve, additional, Singh, Prianka, additional, Kurt, Murat, additional, Kim, Inkyu, additional, Pourrahmat, Mir-Masoud, additional, Friedman, Howard S., additional, Navaratnam, Prakash, additional, and Reardon, Gregory, additional

Published
2023
Full Text
View/download PDF

9. Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study

Author

Au, Trang H, primary, Willis, Connor, additional, Reblin, Maija, additional, Peters, Katherine B, additional, Nghiemphu, Phioanh Leia, additional, Taylor, Jennie W, additional, Colman, Howard, additional, Cohen, Adam L, additional, Ormond, David Ryan, additional, Neil, Elizabeth C, additional, Chakravarti, Arnab, additional, Willmarth, Nicole, additional, Balajonda, Bea Christine, additional, Menon, Jyothi, additional, Ma, Junjie, additional, Bauer, Hillevi, additional, Nelson, Ryan S, additional, Tan, Malinda S, additional, Singh, Prianka, additional, Marshall, Alexander, additional, Korytowsky, Beata, additional, Stenehjem, David, additional, and Brixner, Diana, additional

Published
2023
Full Text
View/download PDF

11. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Author

Kelly, Ronan J, Ajani, Jaffer A, Kuzdzal, Jaroslaw, Zander, Thomas, Van Cutsem, Eric, Piessen, Guillaume, Mendez, Guillermo, Feliciano, Josephine, Motoyama, Satoru, Lièvre, Astrid, Uronis, Hope, Elimova, Elena, Grootscholten, Cecile, Geboes, Karen, Zafar, Syed, Snow, Stephanie, Ko, Andrew H, Feeney, Kynan, Schenker, Michael, Kocon, Piotr, Zhang, Jenny, Zhu, Lili, Lei, Ming, Singh, Prianka, Kondo, Kaoru, Cleary, James M, Moehler, Markus, CheckMate 577 Investigators, Van den Eynde, Marc, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service d'hépato-gastro-entérologie, UCL - (SLuc) Service d'hématologie, Baylor University, MD Anderson Cancer Center [Houston], The University of Texas Health Science Center at Houston (UTHealth), Uniwersytet Jagielloński w Krakowie = Jagiellonian University (UJ), Universitätsklinikum Köln (Uniklinik Köln), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), CHU Lille, Favaloro Foundation, Johns Hopkins University (JHU), Akita University, Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Duke Cancer Institute Durham, Duke University Medical Center, Princess Margaret Hospital, University of Toronto, Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, Ghent University Hospital, Florida Hospital Cancer Institute, University of California [San Francisco] (UC San Francisco), University of California (UC), Bristol-Myers Squibb Company, Dana-Farber Cancer Institute [Boston], Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University (JGU), Bristol Myers Squibb Bristol-Myers Squibb, Ono Pharmaceutical, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of California [San Francisco] (UCSF), University of California, and Johannes Gutenberg - Universität Mainz (JGU)

Subjects
Adult, Male, medicine.medical_specialty, Esophageal Neoplasms, medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Kaplan-Meier Estimate, Adenocarcinoma, 030204 cardiovascular system & hematology, Gastroenterology, B7-H1 Antigen, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Stomach Neoplasms, Internal medicine, Medicine and Health Sciences, medicine, Carcinoma, Humans, 030212 general & internal medicine, Esophagus, Immune Checkpoint Inhibitors, Neoadjuvant therapy, Aged, Aged, 80 and over, Chemotherapy, business.industry, Cancer, Chemoradiotherapy, Adjuvant, General Medicine, Middle Aged, medicine.disease, Neoadjuvant Therapy, Intention to Treat Analysis, 3. Good health, Nivolumab, medicine.anatomical_structure, Chemotherapy, Adjuvant, Carcinoma, Squamous Cell, Female, Esophagogastric Junction, business, Adjuvant, Chemoradiotherapy
Abstract

BackgroundNo adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. MethodsWe conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks for 16 weeks, followed by nivolumab at a dose of 480 mg every 4 weeks) or matching placebo. The maximum duration of the trial intervention period was 1 year. The primary end point was disease-free survival. ResultsThe median follow-up was 24.4 months. Among the 532 patients who received nivolumab, the median disease-free survival was 22.4 months (95% confidence interval [CI], 16.6 to 34.0), as compared with 11.0 months (95% CI, 8.3 to 14.3) among the 262 patients who received placebo (hazard ratio for disease recurrence or death, 0.69; 96.4% CI, 0.56 to 0.86; P

Published
2021

12. Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma

Author

Au, Trang H., primary, Willis, Connor, additional, Reblin, Maija, additional, Peters, Katherine B., additional, Nghiemphu, Phioanh Leia, additional, Taylor, Jennie W., additional, Colman, Howard, additional, Cohen, Adam L., additional, Ormond, D. Ryan, additional, Chakravarti, Arnab, additional, Willmarth, Nicole, additional, Menon, Jyothi, additional, Ma, Junjie, additional, Bauer, Hillevi, additional, Watanabe, Alexandre H., additional, Ulrich, Cornelia M., additional, Singh, Prianka, additional, Marshall, Alexander, additional, Korytowsky, Beata, additional, Stenehjem, David, additional, and Brixner, Diana, additional

Published
2021
Full Text
View/download PDF

13. Caregiver burden by treatment and clinical characteristics of patients with glioblastoma

Author

Au, Trang H., primary, Willis, Connor, additional, Reblin, Maija, additional, Peters, Katherine B., additional, Nghiemphu, Phioanh Leia, additional, Taylor, Jennie W., additional, Colman, Howard, additional, Cohen, Adam L., additional, Ormond, D. Ryan, additional, Chakravarti, Arnab, additional, Willmarth, Nicole, additional, Menon, Jyothi, additional, Ma, Junjie, additional, Bauer, Hillevi, additional, Watanabe, Alexandre H., additional, Ulrich, Cornelia M., additional, Singh, Prianka, additional, Marshall, Alexander, additional, Korytowsky, Beata, additional, Stenehjem, David, additional, and Brixner, Diana, additional

Published
2021
Full Text
View/download PDF

16. Additional file 1 of Real-world study of the impact of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) on quality of life and productivity in Europe

Author

Singh, Prianka, Bennett, Bryan, Bailey, Tom, Taylor-Stokes, Gavin, Rajkovic, Ivana, Contente, Marta, Curtis, Sharon, and Curtis, Chris

Abstract

Additional file 1: Supplementary Table 1. Physician demographics. Supplementary Table 2. Patient scores on FACT-G and subscales overall, by country and reference normative value (30). Supplementary Table 3. Patient scores on FACT H&N questionnaire and subscales overall, by country and reference normative value (31).

Published
2021
Full Text
View/download PDF

17. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

Author

Kelly, Ronan Joseph, primary, Ajani, Jaffer A., additional, Kuzdzal, Jaroslaw, additional, Zander, Thomas, additional, Van Cutsem, Eric, additional, Piessen, Guillaume, additional, Mendez, Guillermo, additional, Feliciano, Josephine Louella, additional, Motoyama, Satoru, additional, Lièvre, Astrid, additional, Uronis, Hope Elizabeth, additional, Elimova, Elena, additional, Grootscholten, Cecile, additional, Geboes, Karen Paula, additional, Zhang, Jenny, additional, Soleymani, Samira, additional, Lei, Ming, additional, Singh, Prianka, additional, Cleary, James M., additional, and Moehler, Markus H., additional

Published
2021
Full Text
View/download PDF

18. Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).

Author

Van Cutsem, Eric, primary, Singh, Prianka, additional, Cleary, James M., additional, Kelly, Ronan Joseph, additional, Moehler, Markus H., additional, Kuzdzal, Jaroslaw, additional, Mendez, Guillermo, additional, Motoyama, Satoru, additional, Elimova, Elena, additional, Grootscholten, Cecile, additional, Sun, Xiaowu, additional, Taylor, Fiona, additional, Lawrance, Rachael, additional, Padilla, Brad, additional, Moreno-Koehler, Alejandro, additional, Zhang, Jenny, additional, Blum, Steven I., additional, and Ajani, Jaffer A., additional

Published
2021
Full Text
View/download PDF

22. QOLP-09. IMPACT OF GLIOBLASTOMA (GBM) PATIENTS’ CLINICAL AND TREATMENT CHARACTERISTICS ON CAREGIVER BURDEN AND QUALITY OF LIFE (QOL)

Author

Au, Trang, primary, Willis, Connor, additional, Peters, Katherine, additional, Colman, Howard, additional, Cohen, Adam, additional, Leia Nghiemphu, P, additional, Taylor, Jennie, additional, Reblin, Maija, additional, Ryan Ormond, D, additional, Willmarth, Nicole, additional, Menon, Jyothi, additional, Ma, Junjie, additional, Singh, Prianka, additional, Marshall, Alexander, additional, Watanabe, Alexandre, additional, Korytowsky, Beata, additional, Stenehjem, David, additional, and Brixner, Diana, additional

Published
2019
Full Text
View/download PDF

27. Impact of glioblastoma (GBM)-related cognitive dysfunction (CD) on caregiver burden: Preliminary results from multi-site study in the U.S.

Author

Au, Trang H., primary, Bauer, Hillevi, additional, Menon, Jyothi, additional, Willis, Connor, additional, Iacob, Eli, additional, Ma, Junjie, additional, Watanabe, Alexandre, additional, Nelson, Ryan, additional, Korytowsky, Beata, additional, Singh, Prianka, additional, Marshall, Alexander, additional, Willmarth, Nicole, additional, Nghiemphu, Phioanh Leia, additional, Dovek, Laura, additional, Peters, Katherine B., additional, Balajonda, Bea, additional, Cohen, Adam Louis, additional, Colman, Howard, additional, Stenehjem, David D., additional, and Brixner, Diana I., additional

Published
2018
Full Text
View/download PDF

28. Survival, costs, and health care resource use by line of therapy in US Medicare patients with newly diagnosed glioblastoma: a retrospective observational study.

Author

Aly, Abdalla, Singh, Prianka, Korytowsky, Beata, Ling, You-Li, Kale, Hrishikesh P, Dastani, Homa B, Botteman, Marc F, and Norden, Andrew D

Subjects
*MEDICAL care use, *NURSING care facilities, *SURGICAL excision, *MEDICARE costs, *SCIENTIFIC observation
Abstract

Background Glioblastoma (GBM) is associated with poor prognosis, large morbidity burden, and limited treatment options. This analysis evaluated real-world treatment patterns, overall survival, resource use, and costs among Medicare patients with GBM. Methods This retrospective observational study evaluated Medicare patients age 66 years or older with newly diagnosed GBM using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data from 2007 through 2013. Patients were followed from diagnosis to death or end of follow-up. An algorithm defined treatment patterns as lines of therapy (LOTs). The Kaplan-Meier method was used to estimate overall survival for the full sample as well as by LOT, surgical resection, Charlson Comorbidity Index (CCI), tumor size, and age. Resource use and costs during the follow-up period were reported in terms of total and per-patient-per-month (PPPM) estimates. Results A total of 4308 patients with GBM were identified (median age, 74 years; CCI of 0, 52%). The most commonly used first LOT was temozolomide (82%), whereas chemotherapy + bevacizumab was most prevalent for second-line (42%) and third-line (58%) therapy. The median overall survival was 5.9 months for resected patients and 3 months for unresected patients, with considerable heterogeneity depending on patient characteristics. A great proportion of patients had claims for an ICU admission (86.2%), skilled nursing facility (76.9%), and home health (56.0%) in the postdiagnosis period. The cumulative mean cost was $95 377 per patient and $18 053 PPPM, mostly attributed to hospitalizations. Conclusions Limited treatment options, poor survival, and economic burden emphasize the need for novel interventions to improve care for Medicare patients with GBM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting

Author

Henk, Henry J., primary, Cao, Feng, additional, Tuell, Kenneth, additional, Price, Kwanza, additional, Singh, Prianka, additional, Mardekian, Jack, additional, Odell, Kevin, additional, Patel, Chad, additional, Tan, Wilson, additional, Sands, George H., additional, Singhal, Shalabh, additional, Trocio, Jeffrey, additional, and Vo, Lien, additional

Published
2018
Full Text
View/download PDF

32. HOUT-19. DEVELOPMENT OF A NOVEL BURDEN SURVEY FOR CAREGIVERS OF GLIOBLASTOMA MULTIFORME (GBM) PATIENTS

Author

Au, Trang, primary, Bauer, Hillevi, additional, Ma, Junjie, additional, Nelson, Ryan, additional, Watanabe, Alexandre, additional, Singh, Prianka, additional, Korytowsky, Beata, additional, Wilson, Elizabeth, additional, Willmarth, Nicole, additional, Cohen, Adam, additional, Colman, Howard, additional, Stenehjem, David, additional, and Brixner, Diana, additional

Published
2017
Full Text
View/download PDF

33. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System

Author

An, JaeJin, primary, Niu, Fang, additional, Zheng, Chengyi, additional, Rashid, Nazia, additional, Mendes, Robert A., additional, Dills, Diana, additional, Vo, Lien, additional, Singh, Prianka, additional, Bruno, Amanda, additional, Lang, Daniel T., additional, Le, Paul T., additional, Jazdzewski, Kristin P., additional, and Aranda, Gustavus, additional

Published
2017
Full Text
View/download PDF

35. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view

Author

Xie, Lin, primary, Vo, Lien, additional, Keshishian, Allison, additional, Price, Kwanza, additional, Singh, Prianka, additional, Mardekian, Jack, additional, Bruno, Amanda, additional, Baser, Onur, additional, Kim, Jully, additional, Tan, Wilson, additional, and Trocio, Jeffrey, additional

Published
2016
Full Text
View/download PDF

36. Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Author

Alpesh, Amin N, primary, Keshishian, Allison, additional, Xie, Lin, additional, Baser, Onur, additional, Price, Kwanza, additional, Vo, Lien, additional, Singh, Prianka, additional, Bruno, Amanda, additional, Mardekian, Jack, additional, Tan, Wilson, additional, Singhal, Shalabh, additional, Patel, Chad, additional, Odell, Kevin, additional, and Trocio, Jeffrey, additional

Published
2015
Full Text
View/download PDF

37. Abstract 19672: Comparison of Major-bleeding Risk and Health Care Costs Among Treatment-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin

Author

Amin, Alpesh, primary, Keshishian, Allison, additional, Xie, Lin, additional, Baser, Onur, additional, Price, Kwanza, additional, Vo, Lien, additional, Singh, Prianka, additional, Bruno, Amanda, additional, Mardekian, Jack, additional, Tan, Wilson, additional, Singhal, Shalabh, additional, Patel, Chad, additional, Odell, Kevin, additional, and Trocio, Jeffrey, additional

Published
2015
Full Text
View/download PDF

39. Comparison of Short-Term Bleeding-Related Health Care Utilization and Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin

Author

Amin, Alpesh, primary, Keshishian, Allison, additional, Xie, Lin, additional, Baser, Onur, additional, Price, Kwanza, additional, Vo, Lien, additional, Singh, Prianka, additional, Bruno, Amanda, additional, Mardekian, Jack, additional, Tan, Wilson, additional, Singhal, Shalabh, additional, Patel, Chad, additional, Odell, Kevin, additional, and Trocio, Jeffrey, additional

Published
2015
Full Text
View/download PDF

40. Warfarin Management and Outcomes in Patients With Nonvalvular Atrial Fibrillation Within an Integrated Healthcare System

Author

An, JaeJin, primary, Niu, Fang, additional, Zheng, Chengyi, additional, Rashid, Nazia, additional, Mendes, Robert, additional, Dills, Diana, additional, Vo, Lien, additional, Singh, Prianka, additional, Bruno, Amanda, additional, Lang, Daniel, additional, Le, Paul, additional, Jazdzewski, Kristin, additional, and Aranda, Gustavus, additional

Published
2015
Full Text
View/download PDF

41. Treatment and Discharge Patterns Among Patients Hospitalized With Nonvalvular Atrial Fibrillation (NVAF) Who Transition From the Inpatient to Outpatient Setting

Author

Trocio, Jeffrey, primary, Bruno, Amanda, additional, Tuell, Kenneth, additional, Price, Kwanza, additional, Singh, Prianka, additional, Mardekian, Jack, additional, Odell, Kevin, additional, Patel, Chad, additional, Tan, Wilson, additional, Henk, Henry, additional, and Vo, Lien, additional

Published
2015
Full Text
View/download PDF

43. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.

Author

Deitelzweig, Steve, Evans, Michael, Hillson, Eric, Trocio, Jeffrey, Bruno, Amanda, Tan, Wilson, Lingohr-Smith, Melissa, Singh, Prianka, and Lin, Jay

Subjects
ATRIAL fibrillation, ATRIAL fibrillation treatment, DRUG therapy, WARFARIN, MEDICATION safety, DRUG efficacy, MEDICAL care costs, PATIENTS, ANTICOAGULANTS, MEDICAL care use, TIME, RETROSPECTIVE studies, INTERNATIONAL normalized ratio
Abstract

Background: Warfarin is efficacious for reducing stroke risk among patients with nonvalvular atrial fibrillation (NVAF). However, the efficacy and safety of warfarin are influenced by its time in therapeutic range (TTR).Objective: To assess differences in healthcare resource utilization and costs among NVAF patients with low (<60%) and high (≥60%) warfarin TTRs in an integrated delivery network (IDN) setting.Methods: Patients with NVAF were identified from an electronic medical record database. Patients were required to have ≥6 international normalized prothrombin time ratio (INR) tests. NVAF patients were grouped into two cohorts: those with warfarin TTR <60% (low TTR) and those with warfarin TTR ≥60% (high TTR). Healthcare resource utilization and costs were evaluated during a 12 month follow-up period. Multivariable regressions were used to assess the impact of different warfarin TTRs on healthcare costs.Results: Among the study population, greater than half (54%, n = 1595) had a low TTR, and 46% (n = 1356) had a high TTR. Total all-cause healthcare resource utilization was higher among patients in the low TTR cohort vs. the high TTR cohort (number of encounters: 70.2 vs. 56.1, p < 0.001). After adjusting for patient characteristics, total all-cause healthcare costs and stroke-related healthcare costs were $2398 (p < 0.001) and $687 (p = 0.02) higher, respectively, for patients in the low TTR cohort vs. the high TTR cohort.Limitations: In this retrospective study, we were only able to evaluate the association and not the causality between healthcare resource utilization and costs with the different warfarin TTRs.Conclusion: Many warfarin-treated NVAF patients have a low warfarin TTR. NVAF patients with low vs. patients with high warfarin TTR used healthcare resources to a greater extent, which was reflected in higher healthcare costs. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

44. Humanistic and economic burden of hepatocellular carcinoma: systematic literature review.

Author

Kohn CG, Singh P, Korytowsky B, Caranfa JT, Miller JD, Sill BE, Marshall AC, and Parikh ND

Subjects
Carcinoma, Hepatocellular pathology, Health Care Costs, Health Status, Humans, Liver Neoplasms pathology, Neoplasm Staging, Patient Reported Outcome Measures, Prognosis, Quality of Life, Survival Rate, Carcinoma, Hepatocellular psychology, Carcinoma, Hepatocellular therapy, Cost of Illness, Liver Neoplasms psychology, Liver Neoplasms therapy
Published
2019

Catalog

Books, media, physical & digital resources
See catalog results